Business Context and Reporting Period
Company: enGene Holdings Inc. (trading as Engene Therapeutics Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 11, 2025
Primary Business: Clinical-stage biopharmaceutical company developing detalimogene voraplasmid (detalimogene) for high-risk non-muscle invasive bladder cancer (NMIBC).
Key Financial Metrics
Liquidity: As of October 31, 2025, the Company held $202.4 million in cash, cash equivalents, and short-term investments.
Revenue, Profit, and Debt: The filing text does not provide specific values for revenue, net income, operating margins, or debt levels for this reporting period.
Material Changes and Clinical Updates
Primary Endpoint Change: Following discussions with the FDA, the primary endpoint for the pivotal Cohort 1 of the Phase 2 LEGEND trial changed from a landmark 12-month complete response (CR) rate to "CR at any time." The key secondary endpoint is now duration of response rate.
Enrollment Status: Cohort 1 (BCG-unresponsive patients with CIS) has completed enrollment of 125 patients. Additional cohorts are actively enrolling: Cohort 2a (30 patients), Cohort 2b (45 patients), and Cohort 3 (36 patients).
Preliminary Efficacy Data (as of October 24, 2025)
| Population | Timepoint | Sample Size (N) | Complete Response (CR) Rate | 95% Confidence Interval |
|---|---|---|---|---|
| Post-Protocol Amendment (Enrolled Q4 2024+) |
Any Time | 62 | 63% | 51-74 |
| 3 Month | 62 | 56% | 44-68 | |
| 6 Month | 37 | 62% | 46-76 | |
| Pre-Protocol Amendment (Enrolled prior to Q4 2024) |
Any Time | 31 | 55% | 38-71 |
| 3 Month | 31 | 55% | 38-71 | |
| 6 Month | 27 | 41% | 25-59 |
Note: The filing notes that Pre-Protocol Amendment Patients demonstrated a markedly lower 12-month CR rate compared to FDA-approved products. Among Post-Protocol Amendment Patients, four patients converted to CR at 6 months after not achieving it at 3 months.
Preliminary Safety Data
- Tolerability: Favorable overall profile.
- Adverse Events: 53 of 125 patients (42%) experienced at least one treatment-related adverse event (TRAE).
- Severity: Most TRAEs were Grade 1/2. Three patients (2.4%) experienced Grade 3 TRAEs. No Grade 4 or 5 TRAEs were reported.
- Discontinuations: No drug discontinuations related to severe adverse events. Dose interruption rate was 1.6%; dose discontinuation rate was 0.8%.
- Common TRAEs: Fatigue (16.8%), Dysuria (12.0%), Bladder Spasm (10.4%), Micturition urgency (10.4%), and Pollakiuria (10.4%).
Guidance, Outlook, and Risks
Outlook: The Company is proceeding with the LEGEND trial under the updated primary endpoint, which aligns with other recent FDA-registered programs for BCG-unresponsive NMIBC. Management hosted a conference call on November 11, 2025, to discuss these data points.
Risks/Contingencies: The filing highlights that preliminary data for Pre-Protocol Amendment Patients showed lower efficacy than approved products, though the protocol amendment and subsequent data from Post-Protocol Amendment Patients show improved response rates. The filing explicitly states that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific details of the FDA agreement regarding the change in primary endpoint from 12-month CR to "CR at any time."
- Review the full slide presentation (Exhibit 99.3) for detailed breakdowns of the 9-month assessment data mentioned for Post-Protocol Amendment Patients.
- Confirm the burn rate and projected runway based on the $202.4 million cash position as of October 31, 2025, given the company is pre-revenue.
- Monitor upcoming data readouts for Cohorts 2a, 2b, and 3 to assess the drug's efficacy in BCG-naïve and papillary-only disease populations.